News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Atrion (ATRI) Reports First Quarter Results



5/10/2013 11:07:53 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

ALLEN, TX--(Marketwired - May 09, 2013) - Atrion Corporation (NASDAQ: ATRI) today announced diluted earnings per share for the first quarter of 2013 were up 24% to $3.28 compared to the first quarter of 2012.

Commenting on the Company's results for the first quarter of 2013 compared to the same period last year, David A. Battat, President & CEO, said, "We are very pleased with the significantly higher sales of our ophthalmic, fluid delivery, and cardiovascular products, resulting in a 15% increase in revenues." Mr. Battat added, "Despite increased spending on research and development and higher charges for depreciation, operating income, one of the best measures of performance, was up 18%. Net income increased 23%, benefiting from the late congressional passage of 2012 and 2013 R&D tax credit legislation; although no credits could be booked in 2012, in the first quarter of this year we were finally able to book those credits earned over five quarters. For the remainder of 2013, the favorable impact of R&D tax credits should return to normal levels, while charges for depreciation and spending on R&D are expected to progressively increase each quarter." Mr. Battat continued, "During the quarter we repurchased 5,030 shares of our stock at an average cost of $200 per share, while cash and short and long term investments increased by $4.2 million in the same period to $48.8 million."

Atrion's revenues for the quarter ended March 31, 2013 were $33,493,000 compared with $29,239,000 in the same period in 2012. Net income in the current year quarter totaled $6,635,000 compared to $5,377,000 in last year's first quarter. On a diluted per share basis, earnings for the period increased to $3.28 as compared to $2.65 in the first quarter of last year.

Atrion Corporation develops and manufactures products primarily for medical applications. The Company's website is www.atrioncorp.com.

Statements in this press release that are forward looking are based upon current expectations and actual results or future events may differ materially. Such statements include, but are not limited to, Atrion's expectations regarding R&D tax credits, charges for depreciation and spending on R&D for the remainder of 2013. Words such as "expects," "believes," "anticipates," "intends," "should", "plans," "will" and variations of such words and similar expressions are intended to identify such forward-looking statements. Forward-looking statements involve risks and uncertainties. The following are some of the factors that could cause actual results or future events to differ materially from those expressed in or underlying our forward-looking statements: changing economic, market and business conditions; acts of war or terrorism; the effects of governmental regulation; competition and new technologies; slower-than-anticipated introduction of new products or implementation of marketing strategies; the Company's ability to protect its intellectual property; changes in the prices of raw materials; changes in product mix; and intellectual property and product liability claims and product recalls. The foregoing list of factors is not exclusive, and other factors are set forth in the Company's filings with the Securities and Exchange Commission.

ATRION CORPORATION CONSOLIDATED STATEMENTS OF INCOME (In thousands, except per share data) (Unaudited) Three Months Ended March 31, 2013 2012 ------------ ------------ Revenues $ 33,493 $ 29,239 Cost of goods sold 17,784 15,410 ------------ ------------ Gross profit 15,709 13,829 Operating expenses 6,309 5,886 ------------ ------------ Operating income 9,400 7,943 Interest income 350 290 Other income (expense), net -- 2 ------------ ------------ Income before income taxes 9,750 8,235 Income tax provision (3,115) (2,858) ------------ ------------ Net income 6,635 5,377 ============ ============ Income per basic share $ 3.28 $ 2.67 ============ ============ Weighted average basic shares outstanding 2,020 2,015 ============ ============ Income per diluted share $ 3.28 $ 2.65 ============ ============ Weighted average diluted shares outstanding 2,024 2,026 ============ ============ ATRION CORPORATION CONSOLIDATED BALANCE SHEETS (In thousands) Mar. 31, Dec. 31, ASSETS 2013 2012 ------------- ------------- (Unaudited) Current assets: Cash and cash equivalents $ 16,012 $ 7,999 Short-term investments 4,415 8,182 ------------- ------------- Total cash and short-term investments 20,427 16,181 Accounts receivable 17,384 13,054 Inventories 24,047 23,779 Prepaid expenses and other 909 3,110 Deferred income taxes 623 623 ------------- ------------- Total current assets 63,390 56,747 Long-term investments 28,365 28,433 Property, plant and equipment, net 58,715 59,268 Other assets 11,431 11,362 ------------- ------------- $ 161,901 $ 155,810 ============= ============= LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities 8,767 7,208 Line of credit -- -- Other non-current liabilities 13,453 13,774 Stockholders' equity 139,681 134,828 ------------- ------------- $ 161,901 $ 155,810 ============= =============


Contact:
Jeffery Strickland
Vice President and Chief Financial Officer
(972) 390-9800



Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES